Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05985954 | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | PHASE1 | RECRUITING | 27 | — | — | Jan 18, 2024 | Mar 28, 2028 | Mar 12, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| BRAF Expansion Cohort | EXPERIMENTAL | 1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab and encorafenib. |
| Cohort A | EXPERIMENTAL | 1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab alone. |
| Name | Type | Description |
|---|---|---|
| Cetuximab | DRUG | Given by IV (vein) |
| Ulixertinib | DRUG | Given by PO |
| Encorafenib | DRUG | Given by PO |
Inclusion Criteria: Patients must meet all of the inclusion criteria to be eligible: 1. Provision of signed Informed Consent prior to any screening procedures being performed. 1. Non-English speaking patients will be eligible for participation with involvement of the MD Anderson Language Assis...